|Mr. John Anthony Sedor||Chairman and Chief Exec. Officer||982.15k||N/A||72|
|Dr. Graham G. Miao M.S., M.B.A., Ph.D.||Pres, Chief Financial Officer and Director||587.93k||N/A||53|
|Mr. Michael J. Golembiewski||Principal Accounting Officer, VP and Corp. Controller||N/A||N/A||N/A|
|Mr. Kenneth R. Pina||Chief Legal & Compliance Officer, Sr. VP and Corp. Sec.||N/A||N/A||58|
|Mr. George P. Jones||VP of Sales and Marketing||N/A||N/A||N/A|
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including neurology, pain, and psychiatry. The companys products comprise Treximet, a fixed dose combination product indicated for the treatment of acute migraine; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; and Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.
Pernix Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 5; Compensation: 8.